Ligand Pharmaceuticals Incorporated · NASDAQ:LGND
Ligand Pharmaceuticals — Q3 2009 Earnings Presentation
19 slides from Ligand Pharmaceuticals's earnings presentation, Nov 5, 2009
Slide 1: Ligand Pharmaceuticals Q3 2009 Presentation
November 5, 2009 Filed by Ligand Pharmaceuticals Incorporated.Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to rule 14a-6 under the Securities and Exchange Act of 1934, as amended.Subject Company: Ligand Pharmaceuticals IncorporatedCommission File No: 001-33093
Slide 2: Safe Harbor Statement
Safe Harbor Statement The following presentation contains forward-looking statements regarding Ligand’s prospects, plans and strategies, drug development programs and collaborations, and the proposed acquisitions of Neurogen and Metabasis by Ligand. Forward-looking statements include financial proje
Slide 3: Additional Information and Where to Find It
Additional Information and Where to Find It Ligand has filed with the SEC and intends to ask the SEC to declare effective a Registration Statement on Form S-4, which includes a proxy statement of Neurogen and other relevant materials in connection with the proposed Neurogen transaction, and intends
Slide 4: Q3 Financial Highlights
Q3 Financial Highlights © LIGAND
Slide 5: Ligand's Strategy
Ligand’s Strategy Invest in promising, large market research programsAcquire high-quality, fully funded partnered assetsAssemble broad portfolio of assets - Many partners, many indications, many different molecules in developmentRun efficient business that is not dependent on equity financings Ligan
Slide 6: Ligand's Two Components Driving Value
Ligand’s Two Components Driving Value Partnership Portfolio Biotech Business Company profile assumes pending mergers close
Slide 7: Biotech Industry Challenges and Solutions
Biotech Industry Challenges and Solutions
Slide 8: Value Drivers for Two Pending Acquisitions
Value Drivers for Two Pending Acquisitions
Slide 9: Pharmacopeia – Highlights
Pharmacopeia – Highlights Less than a year ago, Ligand closed its acquisition of Pharmacopeia In that time, we believe Ligand has emerged as a stronger, more diverse company with substantially greater upside
Slide 10: Ligand's Partnership Portfolio
Ligand’s Partnership Portfolio Largest markets and Largest Companies * Subject to closing Neurogen merger** Subject to closing Metabasis merger
Slide 11: Partnership Portfolio programs under development by partners
Partnership Portfolio 38 programs under development by Ligand’s partners Pre-clinical (47%) Phase I(13%) Phase II (18%) Phase III (11%) NDA/Marketed (11%) Over $700 million in potential Milestone payments plus royalties on future sales Proportion of Programs by stageof development
Slide 12: Ligand's Biotech Business
Ligand’s Biotech Business 5 quality programs targeting multi-billion markets *Subject to closing pending mergers Numerous other pipeline opportunities owned by Ligand
Slide 13: Biotech Business Results
Biotech Business Results 5 molecules discovered or co-discovered by Ligand have been approved and currently 3 are on the market Over 15 licensing deals executed by Ligand Most recent deal struck with GSK for thrombocytopenia drug less than one year ago with 16% royalty rate
Slide 14: Research Highlights
14 Research Highlights © LIGAND
Slide 15: SARMs for Muscle Wasting Disorders
Selective Androgen Receptor Modulators (SARM) for Muscle Wasting Disorders Age-related sarcopenia occurs in 6% of the population aged 55-98Contributes to falls and bone fracturesAccounts for $18.5 Billion in direct U.S. healthcare costsCancer cachexia causes severe loss of muscleCachexia is directly
Slide 16: LGD-4033 SARM Properties
LGD-4033 SARM PropertiesBest-in-class potency and tissue selectivityFull activity on androgen receptor in skeletal muscle and boneWeak, partial activity in prostate and sebaceous glandsOrally-active, safe and effective in animal modelsLGD-4033 Phase I Single Ascending Dose study recently completedUp
Slide 17: Orally-Active Erythropoietin Mimetics
Orally-Active Erythropoietin Mimetics EPO is the hormone regulating production of red blood cellsAnemia is common and represents a large marketAnemia is present in patients with chronic kidney disease and many types of cancerAnemia is also present in many patients with congestive heart failure and c
Slide 18: Selected Additions to Ligand Pipeline
Selected Additions to Ligand Pipeline Neurogen and Metabasis Acquisitions Histamine H3 Receptor Antagonist Potential treatment for narcolepsy and mild cognitive impairmentNeurogen’s lead compound is at an advanced preclinical stageGlucagon Receptor AntagonistGlucagon secretion is abnormal in Type 2
Slide 19: Potential Near-Term Milestone and Events
Potential Near-Term Milestone and Events
Ligand Pharmaceuticals — Q3 2009 Earnings Presentation on 6ix